Treats schizophrenia. ANDA 213626, held by Viwit Pharm. Prochlorperazine Edisylate.
As of Nov 20, 2026, ANDA 213626 (Prochlorperazine Edisylate), held by Viwit Pharm, was first approved by FDA on Sep 28, 2021, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE To control severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 28, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Prochlorperazine EdisylateEQ 5MG BASE/ML · injectable;injection | Prochlorperazine Edisylate | Rx |
| Apr 7, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 28, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters